Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2014; 6(11): 793-799
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.793
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.793
Table 1 Vaptans tested in trials
| Name | Receptor selectivity | Administration | Dose (mg) | Half-life (h) |
| Conivaptan | V1aR/V2R | Oral, IV | 40-80 | 31-78 |
| Tolvaptan | V2R | Oral | 15-60 | 6-8 |
| Lixivaptan | V2R | Oral | 50-400 | 7-10 |
| Satavaptan | V2R | Oral | 5-25 | 14-17 |
| Mozavaptan | V2R | Oral | 30-60 | - |
- Citation: Facciorusso A, Amoruso A, Neve V, Antonino M, Prete VD, Barone M. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol 2014; 6(11): 793-799
- URL: https://www.wjgnet.com/1948-5182/full/v6/i11/793.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i11.793